GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Apollon Formularies PLC (AQSE:APOL) » Definitions » Equity-to-Asset

Apollon Formularies (AQSE:APOL) Equity-to-Asset : 0.53 (As of Jun. 2023)


View and export this data going back to . Start your Free Trial

What is Apollon Formularies Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Apollon Formularies's Total Stockholders Equity for the quarter that ended in Jun. 2023 was £2.11 Mil. Apollon Formularies's Total Assets for the quarter that ended in Jun. 2023 was £3.96 Mil. Therefore, Apollon Formularies's Equity to Asset Ratio for the quarter that ended in Jun. 2023 was 0.53.

The historical rank and industry rank for Apollon Formularies's Equity-to-Asset or its related term are showing as below:

AQSE:APOL' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.53   Med: 0.81   Max: 0.97
Current: 0.53

During the past 11 years, the highest Equity to Asset Ratio of Apollon Formularies was 0.97. The lowest was 0.53. And the median was 0.81.

AQSE:APOL's Equity-to-Asset is ranked worse than
56.41% of 1085 companies
in the Drug Manufacturers industry
Industry Median: 0.59 vs AQSE:APOL: 0.53

Apollon Formularies Equity-to-Asset Historical Data

The historical data trend for Apollon Formularies's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apollon Formularies Equity-to-Asset Chart

Apollon Formularies Annual Data
Trend Jun10 Jun11 Dec12 Dec13 Dec14 Dec17 Dec18 Dec19 Dec20 Dec21
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.68 0.69 0.59 0.96 0.97

Apollon Formularies Semi-Annual Data
Jun11 Jun12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec17 Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Jun23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.96 0.96 0.97 0.83 0.53

Competitive Comparison of Apollon Formularies's Equity-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Apollon Formularies's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Apollon Formularies's Equity-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Apollon Formularies's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Apollon Formularies's Equity-to-Asset falls into.



Apollon Formularies Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Apollon Formularies's Equity to Asset Ratio for the fiscal year that ended in Dec. 2021 is calculated as

Equity to Asset (A: Dec. 2021 )=Total Stockholders Equity/Total Assets
=2.963/3.046
=0.97

Apollon Formularies's Equity to Asset Ratio for the quarter that ended in Jun. 2023 is calculated as

Equity to Asset (Q: Jun. 2023 )=Total Stockholders Equity/Total Assets
=2.114/3.957
=0.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Apollon Formularies  (AQSE:APOL) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Apollon Formularies Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Apollon Formularies's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Apollon Formularies (AQSE:APOL) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
6 Hope Street, Quayside House, Castletown, IMN, IM9 1AS
Apollon Formularies PLC is a London, England and Jamaican based medical cannabis pharmaceutical company specialising in research and treatment of patients with cancer and chronic pain. It is engaged in investing by seeking to acquire a direct and/or indirect interest in projects and assets in the agriculture and logistics sectors and the medicinal cannabis sector. The company focus on opportunities in Africa and Europe. It has created proprietary hybrid medical cannabis pharmaceutical strains, technology, formulations, and treatment products.

Apollon Formularies (AQSE:APOL) Headlines

From GuruFocus

Sobering Findings About Student Debt

By OPM Insights Nelson Hsu 11-07-2015

The Yacktman Focused Fund's Top Growth Stocks

By Dianne Tordillo Dianne Tordillo 01-25-2013

FPA Capital Fund Q1 2013 Commentary

By Holly LaFon Holly LaFon 04-24-2013

FPA Capital Fund Comments on Apollo Education Group Inc

By Vera Yuan Vera Yuan 02-19-2015

Update from FPA Capital - Seven Changes to Portfolio

By Sally Jones Sally Jones 07-14-2013

FPA Capital Fund Comments on Apollo Education Group Inc

By Vera Yuan Vera Yuan 05-22-2015

FPA Capital Fund 4th Quarter 2015 Commentary

By Holly LaFon Holly LaFon 02-08-2016

5 Stocks to Avoid - January 2017

By Benjamin Clark Benjamin Clark 01-14-2017

FPA Capital Comments on Apollo

By Holly LaFon 07-29-2013